Date	Chamber	Action
1/11/2011	House	Session Sine Die

Synopsis As Introduced
Urges the Congress of the United States to help ensure that any new legislation allowing for approval of biosimilar drugs includes provisions to ensure that the public health is protected by adequate testing of biosimilar products and physician control over which treatments their patients receive, and that the legislation preserves the ability to create innovative and important new biotechnology therapies.

Actions 

Date	Chamber	Action
3/10/2009	House	Filed with the Clerk by Rep. Maria Antonia Berrios
3/11/2009	House	Referred to Rules Committee
3/16/2009	House	Assigned to Bio-Technology Committee
12/1/2009	House	Rule 19(b) / Re-referred to Rules Committee
1/11/2011	House	Session Sine Die

Back To Top